Society of Thoracic Surgeons - Congenital

APRIL 1, 2024

Resource Isolated Tricuspid Valve Surgery Risk Calculator kchalko Mon, 04/01/2024 - 13:31 Isolated Tricuspid Valve Surgery Risk Calculator Existing literature on national surgical outcomes of isolated tricuspid valve repair or replacement is based on data from over a decade ago and may not reflect current practice results.

Tricuspid 86

Tricuspid Outcomes 86

DAIC

FEBRUARY 2, 2024

Photo: Edwards Lifesciences milla1cf Fri, 02/02/2024 - 09:33 February 2, 2024 — Edwards Lifesciences Corporation announced the company’s EVOQUE tricuspid valve replacement system is the first transcatheter therapy to receive U.S. Food and Drug Administration (FDA) approval for the treatment of tricuspid regurgitation (TR).

Tricuspid 100

Tricuspid Quality of Life Bicuspid/Mitral Innovation 100

European Journal of Heart Failure

MARCH 7, 2024

Changes in right ventricular (RV) function and clinical outcomes after tricuspid transcatheter edge-to-edge repair (T-TEER). We investigated association of RV function and its post-procedural changes with clinical outcomes in patients undergoing T-TEER.

Tricuspid 76

Tricuspid Outcomes Heart Failure Hospital 76

Heart BMJ

FEBRUARY 23, 2024

Significant secondary tricuspid regurgitation (STR) has increasing prevalence with age, it is associated with impaired quality of life, and it is an independent predictor of patients’ morbidity and mortality. 3 4 However, the association of RA function with outcomes in patients with STR received less attention.

Tricuspid 74

Tricuspid Quality of Life Outcomes 74

DAIC

APRIL 30, 2024

Tricuspid Valve Repair Existing literature on national surgical outcomes of isolated tricuspid valve repair or replacement is based on data from over a decade ago and may not reflect current practice results. Analysis of 13,587 patients undergoing isolated tricuspid valve surgery from 2017 to 2023 revealed a 5.5%

TAVR 111

TAVR Aortic valve Tricuspid Coronary Artery Bypass Graft 111

DAIC

JUNE 11, 2024

Columbia University Irving Medical Center’s Division of Cardiology has announced its launch of the Mitral & Tricuspid Center. Tricuspid and mitral valves are debilitating conditions that can lead to arrhythmias, hypertension, and heart failure.

Tricuspid 52

Tricuspid Bicuspid/Mitral Heart Valves Innovation 52

Frontiers in Cardiovascular Medicine

JUNE 12, 2024

BackgroundSevere tricuspid regurgitation (TR) causing cyanosis with patent foramen ovale (PFO) and right-to-left atrial shunting requires a precise diagnosis for optimal therapy. Tricuspid valve prolapse (TVP) can lead to TR and is sometimes overlooked, especially in complex cases with factors like pulmonary hypertension (PH).

Tricuspid 52

Tricuspid Pulmonary Echocardiogram Hypertension 52

Open Heart

DECEMBER 15, 2022

Introduction Isolated tricuspid valve surgery (TVS) may be associated with high morbidity and mortality. The primary outcome was a composite of mortality and congestive heart failure at 1 year. The primary outcome occurred in 16 patients (27%) with a 1-year mortality of 7%. respectively, p<0.05).

Tricuspid 52

Tricuspid Outcomes Congenital Heart Disease Congenital 52

American College of Cardiology

DECEMBER 12, 2024

The goal of the TRILUMINATE Pivotal trial was to evaluate percutaneous tricuspid valve transcatheter edge-to-edge repair (TEER) compared with medical therapy among patients with symptomatic severe tricuspid regurgitation.

Tricuspid 45

Tricuspid Outcomes Article 45

Frontiers in Cardiovascular Medicine

MARCH 20, 2025

ObjectivesRegistered, prospective, multicenter study of the short-term clinical outcomes of a novel transcatheter aortic valve system (Xcor system, Saint Medical Technology, Inc., Procedural, in-hospital, and follow-up clinical outcomes were evaluated after procedures.ResultsThe average age of the 130 patients was 71.24.4

Aortic valve 52

Aortic valve Aortic Bicuspid/Mitral Stenosis 52

American College of Cardiology

AUGUST 5, 2024

What are the 1-year clinical outcomes of subjects treated by tricuspid transcatheter edge-to-edge repair (T-TEER) with the TriClip system in a contemporary real-world setting?

Tricuspid 45

Tricuspid Outcomes Article 45

Journal of Cardiovascular Electrophysiology

MARCH 17, 2025

Distribution Variance of Focal Atrial Tachycardia Foci and Long-Term Outcomes After Ablation. FAT in middle-aged and old adult patients was more likely to originate from the crista terminalis, tricuspid annulus, non-coronary cusp, and para-His. After a mean follow-up of 47.2 months, FAT recurred in 57 patients.

Tachycardia 40

Tachycardia Ablation Outcomes Tricuspid 40

HeartRhythm

APRIL 30, 2024

Tricuspid valve (TV) disease associated with right ventricular leads has been linked to tricuspid leaflet restriction, resulting in worsening tricuspid regurgitation (TR).

Tricuspid 40

Tricuspid Outcomes 40

DAIC

FEBRUARY 21, 2024

Henry Ford Health's Center for Structural Heart Disease team delivered its first in Michigan FDA-approved VOQUE Transcatheter Tricuspid Valve Replacement System to a heart failure patient on February 13, 2024 at Henry Ford Hospital in Detroit. million Americans have moderate to severe tricuspid regurgitation. to receive the device.

Heart Failure 105

Heart Failure Open-Heart Surgery Tricuspid Heart Disease 105

Journal of Cardiovascular Electrophysiology

MARCH 7, 2024

Abstract Introduction Transvenous leads have been implicated in tricuspid valve (TV) dysfunction, but limited data are available regarding the effect of extracting leads across the TV on valve regurgitation. Methods We studied 321 patients who had echocardiographic data before and after lead extraction.

Tricuspid 40

Tricuspid Outcomes Article 40

European Journal of Heart Failure

NOVEMBER 8, 2023

Abstract Aim Functional or secondary tricuspid regurgitation (STR) is the most common phenotype of tricuspid regurgitation (TR) with atrial STR (ASTR) and ventricular STR (VSTR) being recently identified as two distinct entities. ASTR vs. VSTR) are lacking. ASTR vs. VSTR) are lacking.

Tricuspid 40

Tricuspid Outcomes Atrial Fibrillation Pulmonary 40

American College of Cardiology

OCTOBER 27, 2024

What is the clinical impact of tricuspid regurgitation (TR) reduction with tricuspid transcatheter edge-to-edge repair (T-TEER)?

Tricuspid 54

Tricuspid Outcomes Article 54

Medical Xpress - Cardiology

MARCH 13, 2025

Tricuspid regurgitation (TR) is a known prognostic factor in heart diseases like heart failure and degenerative MR. It is also frequently observed in AFMR patients, making it crucial to understand its impact on AFMR outcomes.

Tricuspid 40

Tricuspid Heart Failure Bicuspid/Mitral Heart Disease 40

Circulation: Cardiovascular Interventions

OCTOBER 17, 2023

BACKGROUND:Data concerning the outcomes of transcatheter aortic valve replacement in type 0 bicuspid aortic stenosis (AS) are scarce. Circulation: Cardiovascular Interventions, Ahead of Print. These observations merit further exploration in prospective international registries and randomized controlled trials.

Aortic valve 40

Aortic valve Bicuspid/Mitral Aortic Tricuspid 40

American College of Cardiology

SEPTEMBER 11, 2024

What are the 3-year outcomes of tricuspid transcatheter edge-to-edge repair (T-TEER) with the TriClip implant for the treatment of severe symptomatic tricuspid regurgitation (TR)?

Tricuspid 42

Tricuspid Outcomes Article 42

American College of Cardiology

OCTOBER 21, 2024

Patients with moderate or severe tricuspid regurgitation (TR) prior to undergoing TAVR or mitral transcatheter edge-to-edge repair (TEER), when compared to patients with no or mild TR, were associated with worse health status and clinical outcomes, according to a study published in JACC: Cardiovascular Interventions.

TAVR 48

TAVR Bicuspid/Mitral Tricuspid Outcomes 48

European Journal of Heart Failure

FEBRUARY 19, 2024

Tricuspid regurgitation (TR): frequency, clinical presentation, management and outcome among patients with severe left-sided valvular heart disease in Europe. ESC-EORP, European Society of Cardiology-EURObservational Research Programme; TV, tricuspid valve.

Tricuspid 40

Tricuspid Heart Disease Bicuspid/Mitral Heart Valves 40

Journal of the American Heart Association

MARCH 7, 2025

BackgroundTranscatheter closure of perimembranous ventricular septal defects in children is a highly effective procedure, but it can result in tricuspid regurgitation (TR).

Risk Factors 40

Risk Factors Tricuspid Pediatrics Outcomes 40

Circulation

NOVEMBER 11, 2024

Tricuspid regurgitation was reduced to ≤moderate in 82.5% and 95.1%, respectively.Conclusions:One-year experience using the K-Clip tricuspid annuloplasty system demonstrated high survival rates, low complications and durable improvements in TR reduction, functional status, and quality of life for patients with severe secondary TR.

Tricuspid 40

Tricuspid Quality of Life Heart Failure Cardiomyopathy 40

Heart BMJ

MARCH 12, 2024

Objective Tricuspid regurgitation (TR) is a progressive disease with high mortality and limited medical treatment options, and its association with atrial fibrillation (AF) has been documented. The primary outcome was at least one grade TR reduction with its main determinants evaluated. years, 50% female) were analysed. of severe TR).

Tricuspid 40

Tricuspid Atrial Fibrillation Ablation Document 40

Circulation

OCTOBER 23, 2024

BACKGROUND:This study aimed to compare the incidence and prognostic implications of new-onset conduction disturbances after surgical aortic valve replacement (SAVR) in patients with bicuspid aortic valve (BAV) aortic stenosis (AS) versus patients with tricuspid aortic valve (TAV) AS (ie, BAV-AS and TAV-AS, respectively).

Aortic valve 40

Aortic valve Bicuspid/Mitral Aortic Tricuspid 40

American College of Cardiology

APRIL 10, 2025

Transcatheter tricuspid valve replacement (TTVR) may be a "feasible and effective approach" for treating high-risk patients with severe tricuspid regurgitation (TR) who have limited therapeutic options, based on one-year outcomes of the TRAVEL study.

Tricuspid 48

Tricuspid Outcomes Article 48

Journal of the American Heart Association

APRIL 10, 2025

BackgroundBicuspid aortic valves are associated with ascending aortic pathology, but their impact on longterm outcomes, including aortic growth and adverse events, remains unclear.Methods and ResultsThis prospective cohortstudy included adult patients undergoing aortic valve surgery or ascending aortic surgery at a single center (20072013).

Aortic valve 51

Aortic valve Aortic Bicuspid/Mitral Tricuspid 51

Circulation: Cardiovascular Interventions

JANUARY 20, 2025

Circulation: Cardiovascular Interventions, Volume 18, Issue 1 , Page e014991, January 1, 2025.

Tricuspid 40

Tricuspid Cardiovascular Interventions Circulation Outcomes 40

Frontiers in Cardiovascular Medicine

JANUARY 17, 2024

We would like to highlight the role of multi-modality cardiac imaging demonstrated in this case, as well as the limited surgical data and poor outcomes in advanced disease with higher peri-operative complications.

Tricuspid 64

Tricuspid Heart Disease Outcomes 64

The American Journal of Cardiology

MAY 2, 2024

Publication date: Available online 1 May 2024 Source: The American Journal of Cardiology Author(s): Srinivasa Potluri

Tricuspid 40

Tricuspid Bicuspid/Mitral Outcomes 40

Circulation: Cardiovascular Interventions

NOVEMBER 9, 2023

Background:There are limited data about changes in cardiac function (cardiac reverse remodeling) and heart failure indices after transcatheter tricuspid valve-in-valve replacement (TT-VIVR). Circulation: Cardiovascular Interventions, Ahead of Print.

Congenital Heart Disease 40

Congenital Heart Disease Tricuspid Heart Failure Congenital 40

Journal of the American Heart Association

JANUARY 31, 2024

BackgroundThere are limited data on the efficacy and safety of direct oral anticoagulants (DOACs) in patients with atrial fibrillation with significant tricuspid regurgitation (TR), which can lead to hepatic dysfunction and intestinal malabsorption. Journal of the American Heart Association, Ahead of Print. 1.06];P=0.11). 1.06];P=0.11).

Atrial Fibrillation 40

Atrial Fibrillation Tricuspid Embolism Hemorrhage 40

Circulation: Cardiovascular Quality & Outcomes

FEBRUARY 3, 2025

Circulation: Cardiovascular Quality and Outcomes, Ahead of Print. BACKGROUND:Validly measuring disease-specific health status is critical in patients with severe tricuspid regurgitation (TR) to quantify the benefit of different interventions.

Tricuspid 40

Tricuspid Quality of Life Cardiomyopathy Circulation 40

Frontiers in Cardiovascular Medicine

JULY 30, 2024

Traditional transvenous pacemakers consist of a pacemaker generator usually positioned surgically in the upper left chest on the pectoral muscle fascia and one or more leads positioned through the veins to the right atrium and across the tricuspid valve to the right ventricular apex.

Pacemaker 52

Pacemaker Tricuspid Bradycardia Heart Failure 52

Heart BMJ

DECEMBER 20, 2023

In a cohort of patients with liver metastases of midgut neuroendocrine tumours (NETs), we aimed to describe the perioperative management and short-term outcomes of CHD. Tricuspid valve replacement was performed in 26 (53%) patients including 19 (73%) cases of combined pulmonary valve replacement.

Heart Disease 40

Heart Disease Tricuspid Outcomes Heart Failure 40

Circulation

NOVEMBER 11, 2024

While TR can worsen the clinical outcomes in HF patients, its impact on gender, racial and socioeconomic factors remains largely unexplored. Background:Tricuspid regurgitation (TR) is a common occurrence in patients with heart failure (HF), and its role in disease progression has gained attention in recent years.

Heart Failure 40

Heart Failure Tricuspid Outcomes Medicare 40